A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin ® in healthy Chinese male subjects

The biosimilar landscape for malignancies continues to grow, with several biosimilars for reference product bevacizumab currently available. Bevacizumab has been shown to be well tolerated; however, the safety...

Source: BMC Clinical Pharmacology - May 27, 2023 Category: Drugs & Pharmacology Authors: Hongtao Li, Xiangdi Zhao, Jing Xie, Xingyu Zhu, Yue Su, Cuixia He, Jiaxiang Ding, Minhui Zhu, Yuanyuan Xu, Ying Wang, Rongfang Shan, Bingyan Liu, Yuzhou Ding, Yuanyuan Liu, Huan Zhou and Yunqiu Xie Tags: Research Source Type: research